A brain tumor is a mass or growth of abnormal cells in your brain. Many different types of brain tumors exist. Some brain tumors are noncancerous (benign), and some brain tumors are cancerous (malignant). The global Brain Tumor Diagnosis & Therapeutics market is expected to grow proportionally with the rising incidence of brain tumour and increasing death rate over the forecast period.
As per data of the American Society of Clinical Oncology (ASCO), this year, an estimated 24,530 adults (13,840 men and 10,690 women) in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord. About 3,460 children under the age of 15 will also be diagnosed with a brain or CNS tumor this year. In addition, Brain and other nervous system cancer is the 10th leading cause of death for men and women. It is estimated that 18,600 adults (10,500 men and 8,100 women) will die from primary cancerous brain and CNS tumors this year.
The growth of this market is highly influenced by several crucial factors such as innovations in drug delivery to brain cancer cells, the growing prevalence of brain cancer, the rising aging population, and growing incidences of cancer via chemical exposure. Moreover, several government bodies such as International Brain Tumor Alliance, the WHO, and American Brain Tumor Association have come together for research of treatment to cure the disease. This factor has played an important role in the development of the global Brain Tumor Diagnosis & Therapeutics market.
On the contrary, exponentially high costs of diagnostic and treatment are some key challenges that the market is estimated to face in the forthcoming years
Covid-19 Impact on Brain Tumor Diagnosis & Therapeutics Market
In addition, the current Brain Tumor Diagnosis & Therapeutics Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Brain Tumor Diagnosis & Therapeutics Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Brain Tumor Diagnosis & Therapeutics Market Segment Overview
According to Product Type, the Primary Brain Tumor is the largest segment in the Brain Tumor Diagnosis & Therapeutics market. Meningioma is the sub-segment that shows a significant growth in the market. Meningioma is most prevalent across the world. It has been observed that in the Asia Pacific and Europe, CNS and brain tumors are the third most common cancer among young adults and juveniles, causing most of the cancer-related deaths in this age group.
Based on Diagnosis Type, the CT Scan segment has significant growth in the market. CT-Scan is the most preferred choice for brain cancer diagnosis. This is due to their ability to effectively differentiate between bone masses and elaborate soft tissues, also offering the option to click 3D images in a series at multiple angles. Additionally, technological progressions in innovative mobile CT-Scan devices are also projected to support the growth of the CT-Scan diagnosis segment throughout the forecast period. By Treatment Type, Surgery is expected to be the leading contributing segment to the market. Surgery has remained the most preferable primary treatment for a brain tumor. It has been recognized as the first and the only treatment for most types of brain tumors.
Brain Tumor Diagnosis & Therapeutics Market, By Product Type
- Primary Brain Tumor
- Meningioma
- Gliomas
- Astrocytomas
- Pituitary Tumors
- Secondary Brain Tumor
· CT Scan
· MRI
· PET-CT Scan
· Molecular Testing
· EEG
Brain Tumor Diagnosis & Therapeutics Market, By Treatment Type
· Surgery
· Radiation Therapy
· Targeted Therapy
· Chemotherapy
· Immunotherapy
Brain Tumor Diagnosis & Therapeutics Regional Overview
In terms of region, North America accounted for the largest share in the Brain Tumor Diagnosis & Therapeutics market. The U.S. is a prominent place for the market. Important factors such as a large number of people diagnosed with a brain tumor, increasing research and development activities, technological progressions, and growing healthcare awareness about the treatment and management of brain tumor are booting the growth of the market in this region. Similarly, Europe is another major region for the market, is expected that the European market shows noteworthy growth during the forecast period. The growing prevalence of brain tumors disease, the increasing old age population, and the government’s initiative about growing awareness of advanced technologies are some of the crucial factors that contribute more to an expansion of the brain tumor diagnosis and treatments market in Europe. Likewise, the market in the Asia Pacific is expected to witness remarkable growth in the forecast period. Increasing cases of brain tumor, emerging healthcare sector, and a good awareness of people about the treatment of diseases like Cancer are some key aspects that majorly support the development of the market in this region.
Brain Tumor Diagnosis & Therapeutics Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Brain Tumor Diagnosis & Therapeutics Market, Key Players
· Pfizer, Inc.
· Toshiba Medical Systems
· GE Healthcare
· AstraZeneca
· Merck & Co., Inc.
· Siemens Healthineers
· Carestream Health
· Hitachi Medical Corporation
· Philips Healthcare
· Shimadzu Corporation
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Brain Tumor Diagnosis & Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product Type
- 5.2.1. Primary Brain Tumor
- 5.2.1.1. Meningioma
- 5.2.1.2. Gliomas
- 5.2.1.3. Astrocytomas
- 5.2.1.4. Pituitary Tumors
- 5.2.2. Secondary Brain Tumor
- 5.2.1. Primary Brain Tumor
- 5.3. Market Analysis, Insights and Forecast – By Diagnosis Type
- 5.3.1. CT Scan
- 5.3.2. MRI
- 5.3.3. PET-CT Scan
- 5.3.4. Molecular Testing
- 5.3.5. EEG
- 5.4. Market Analysis, Insights and Forecast – By Treatment Type
- 5.4.1. Surgery
- 5.4.2. Radiation Therapy
- 5.4.3. Targeted Therapy
- 5.4.4. Chemotherapy
- 5.4.5. Immunotherapy
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East and Africa
6. North America Brain Tumor Diagnosis & Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product Type
- 6.2.1. Primary Brain Tumor
- 6.2.1.1. Meningioma
- 6.2.1.2. Gliomas
- 6.2.1.3. Astrocytomas
- 6.2.1.4. Pituitary Tumors
- 6.2.2. Secondary Brain Tumor
- 6.2.1. Primary Brain Tumor
- 6.3. Market Analysis, Insights and Forecast – By Diagnosis Type
- 6.3.1. CT Scan
- 6.3.2. MRI
- 6.3.3. PET-CT Scan
- 6.3.4. Molecular Testing
- 6.3.5. EEG
- 6.4. Market Analysis, Insights and Forecast – By Treatment Type
- 6.4.1. Surgery
- 6.4.2. Radiation Therapy
- 6.4.3. Targeted Therapy
- 6.4.4. Chemotherapy
- 6.4.5. Immunotherapy
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Brain Tumor Diagnosis & Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product Type
- 7.2.1. Primary Brain Tumor
- 7.2.1.1. Meningioma
- 7.2.1.2. Gliomas
- 7.2.1.3. Astrocytomas
- 7.2.1.4. Pituitary Tumors
- 7.2.2. Secondary Brain Tumor
- 7.2.1. Primary Brain Tumor
- 7.3. Market Analysis, Insights and Forecast – By Diagnosis Type
- 7.3.1. CT Scan
- 7.3.2. MRI
- 7.3.3. PET-CT Scan
- 7.3.4. Molecular Testing
- 7.3.5. EEG
- 7.4. Market Analysis, Insights and Forecast – By Treatment Type
- 7.4.1. Surgery
- 7.4.2. Radiation Therapy
- 7.4.3. Targeted Therapy
- 7.4.4. Chemotherapy
- 7.4.5. Immunotherapy
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Brain Tumor Diagnosis & Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product Type
- 8.2.1. Primary Brain Tumor
- 8.2.1.1. Meningioma
- 8.2.1.2. Gliomas
- 8.2.1.3. Astrocytomas
- 8.2.1.4. Pituitary Tumors
- 8.2.2. Secondary Brain Tumor
- 8.2.1. Primary Brain Tumor
- 8.3. Market Analysis, Insights and Forecast – By Diagnosis Type
- 8.3.1. CT Scan
- 8.3.2. MRI
- 8.3.3. PET-CT Scan
- 8.3.4. Molecular Testing
- 8.3.5. EEG
- 8.4. Market Analysis, Insights and Forecast – By Treatment Type
- 8.4.1. Surgery
- 8.4.2. Radiation Therapy
- 8.4.3. Targeted Therapy
- 8.4.4. Chemotherapy
- 8.4.5. Immunotherapy
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Brain Tumor Diagnosis & Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product Type
- 9.2.1. Primary Brain Tumor
- 9.2.1.1. Meningioma
- 9.2.1.2. Gliomas
- 9.2.1.3. Astrocytomas
- 9.2.1.4. Pituitary Tumors
- 9.2.2. Secondary Brain Tumor
- 9.2.1. Primary Brain Tumor
- 9.3. Market Analysis, Insights and Forecast – By Diagnosis Type
- 9.3.1. CT Scan
- 9.3.2. MRI
- 9.3.3. PET-CT Scan
- 9.3.4. Molecular Testing
- 9.3.5. EEG
- 9.4. Market Analysis, Insights and Forecast – By Treatment Type
- 9.4.1. Surgery
- 9.4.2. Radiation Therapy
- 9.4.3. Targeted Therapy
- 9.4.4. Chemotherapy
- 9.4.5. Immunotherapy
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Pfizer, Inc.
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Toshiba Medical Systems
- 10.6. GE Healthcare
- 10.7. AstraZeneca
- 10.8. Merck & Co., Inc.
- 10.9. Siemens Healthineers
- 10.10. Carestream Health
- 10.11. Hitachi Medical Corporation
- 10.12. Philips Healthcare
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
